News Briefs


GNC provides holistic health solutions with 50 Plus line

GNC Mega Men and Women’s 50+ Multivitamin Gummies

GNC is expanding upon its holistic health solutions by unveiling a new way consumers who are aged 50 years old and older can obtain their essential daily nutrients.

New from the Pittsburgh-based company is the Mega Men and Women’s 50+ Multivitamin Gummies.

‘GNC Mega Men and GNC Women’s products are great solutions for consumers that need daily support to Live Well,” said Kevin Maloberti, vice president of merchandising at GNC. “These gummies provide clinically studied blends that are shown to work throughout your wellness journey. Our new GNC Mega Men and  GNC Womens  50+ Multivitamin Gummies are a celebration of our commitment to consumer-centric innovation which we hope to see amplify the well-being and everyday health of our consumers.”

Both new launches provide consumers with vitamins and minerals to aid in supporting overall enhanced quality of life and longevity, the company said.

GNC Mega Men and Women’s 50+ Multivitamin Gummies are available for purchase at GNC stores and online.


Native’s Candy Shop collection sweetens the personal care aisle

native candy shop collection

Native is bringing the sweetness of a candy store to the personal care aisle with its new Candy Shop collection.

Featuring four sweet scents, the line will be available in deodorant, plastic-free deodorant, body wash, sensitive deodorant and shampoo and conditioner options.

Scents in the line include:

  • Gummy Bear: A zesty meets gummy-licious fruity fragrance that comes in deodorant, plastic-free deodorant, body wash and shampoo and conditioner options;
  • Sour Berry Ropes: A citrusy twist on mixed berries that packs a sweet and sour punch in deodorant and body wash products;
  • Sweet Cinnamon Hearts: A nostalgic blend of nutty spices with a candy coating. The cinnamon-scented line comes in deodorant, sensitive deodorant and body wash options; and
  • Strawberry and Vanilla Taffy: A blend of creamy vanilla, strawberry, caramel and coconut fragrances in a deodorant, sensitive deodorant and body wash options.

Consumers can find Native’s Candy Shop collection available for purchase online.   


Ahold Delhaize begins share buyback program

ahold delhaize teaser

Ahold Delhaize announced the beginning of its 1 billion Euro share buyback program, which is expected to be completed before the end of 2023.

The purpose of the program is to help reduce the capital of the company by canceling all or part of the common shared acquired through the program, the organization shared.

Executed within the limits of relevant laws and regulations, the existing authority granted Ahold Delhaize’s 2022 annual general meeting of shareholders on April 12, 2022, and the authority if granted by the annual general meeting on April 12, 2023.

The share buyback program is executed in one or several tranches. For each of them, an intermediary is mandated to execute the purchase of the shares at his own discretion during open and closed periods in compliance with the Market Abuse Regulation and within pre-defined execution parameters.

Shares are bought in the market and accumulated on the treasury share account until cancellation. Pursuant to the relevant statutory provisions, cancellation may not be effected earlier than two months after a resolution to cancel shares is adopted and publicly announced. Ahold Delhaize is committed to the share buyback program, but the program is subject to changes in corporate activities, such as but not limited to material M&A activity.


Olay combines niacinamide, peptides to strengthen skin

Olay Regenerist Niacinamide + Peptide 24 Face Moisturizer

There’s a new Olay skin care product in town.

The brand launched its new Regenerist Niacinamide + Peptide 24 Face Moisturizer, which looks to strengthen skin, even complexions and visibly correct wrinkles.

Featuring a formula that provides 24-hour hydration that looks to hydrate and repair the skin for a stronger barrier, it contains 99% pure niacinamide, peptides and glycerin to penetrate 10 layers deep in the skin’s surface, the company said.  

Olay’s Regenerist Niacinamide + Peptide 24 Face Moisturizer retails for $30.


Roche receives FDA nod for Lunsumio

FDA approval stamp

The Food and Drug Administration has approved Roche’s Lunsumio (mosunetuzumab-axgb) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Lunsumio, a CD20xCD3 T-cell engaging bispecific antibody, represents a new class of fixed-duration cancer immunotherapy, which is off-the-shelf and readily available, so that patients do not have to wait to start treatment. Lunsumio will be available in the United States in the coming weeks, the company said.

“This approval is a significant milestone for people with relapsed or refractory follicular lymphoma, who have had limited treatment options until now,” said Elizabeth Budde, Haematologic Oncologist and associate professor at the City of Hope division of Lymphoma, department of Hematology and Hematopoietic Cell Transplantation, and Lunsumio clinical trial investigator. “As a first-in-class T-cell engaging bispecific antibody that can be initiated in an outpatient setting, Lunsumio’s high response rates and fixed-duration could change the way advanced follicular lymphoma is treated.”

“Despite treatment advances, follicular lymphoma remains incurable and relapse is common, with outcomes worsening following each consecutive treatment,” said Levi Garraway, Roche’s chief medical officer and head of global product development. “Lunsumio represents our first approved T-cell engaging bispecific antibody and builds on our legacy of more than 20 years of innovation in blood cancer.”


Gilead Sciences receives FDA OK for Sunlenca

The words approved in red capitalized letters

The Food and Drug Administration approved Gilead Sciences’ Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with human immunodeficiency virus type 1 (HIV-1), whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance or safety considerations.

After the starting dose is completed, Sunlenca is administered as subcutaneous (under the skin) injections once every six months, allowing convenient dosing for patients.

"Today's approval ushers in a new class of antiretroviral drugs that may help patients with HIV who have run out of treatment options," said Debra Birnkrant, director of the division of antivirals in the FDA's Center for Drug Evaluation and Research. "The availability of new classes of antiretroviral medications may possibly help these patients live longer, healthier lives."

Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus' protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle. Sunlenca's starting dose is given as oral tablets and subcutaneous injections, followed by maintenance injections every six months; Sunlenca is given in combination with other antiretroviral(s).